Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma - NBC News

The Story At A Glance

• • Merck and Moderna developed a personalized mRNA vaccine to prevent melanoma recurrence.


• • Clinical trials show the vaccine combined with Keytruda reduces recurrence or death risk by 44 to 49 percent.


• • Moderna stock surged 133 percent following the successful late stage trial results.

Context
The program utilizes mRNA technology to target specific mutations within an individual patient's tumor. This approach aims to address the high recurrence rates associated with advanced skin cancer.

Christian Perspective
While medical advancements can preserve the life God has granted, we must remain wary of the mRNA platform used during recent mandates. True healing and the preservation of the biological body are ultimately under God's sovereignty.

Implications
The massive profit surges for these corporations highlight a growing divide between medical advancement and the financial interests of globalist entities. We must ensure that life saving technology does not become a tool for further bodily autonomy violations.

Broader Trends
The rapid expansion of mRNA technology reflects a shift toward highly centralized and controlled medical paradigms. This trend often aligns with the interests of a globalist elite seeking to manage human biology through corporate gatekeeping.

Takeaway
Support medical innovation that respects individual liberty and biological integrity. Remain vigilant against any attempts to use these technologies to bypass parental rights or mandate medical procedures. Prioritize the health of the American family through natural wellness and traditional values.